Home › Trial NCT05487651
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
- Trial IDNCT05487651
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorAthenex, Inc.
- Enrollment36
- Start date2022-10-01
- ConditionsNHL, Relapsed, Adult · B-cell Lymphoma · B-cell Leukemia · DLBCL - Diffuse Large B Cell Lymphoma · ALL, Adult B Cell · ALL, Childhood
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.